NCT07505771 2026-04-06
A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer
Immunome, Inc.
Phase EARLY_PHASE1 Recruiting
Clinical Trials
226 trialsNCT06736275 2026-04-03
A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors
Jiangsu Nutai Biologics Co., Ltd
Phase EARLY_PHASE1 Completed
NCT07033689 2026-04-03
Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)
SONIRE Therapeutics Inc.
Phase EARLY_PHASE1 Recruiting
NCT07505069 2026-04-01
Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors
Nanolattix Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT07376642 2026-03-30
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Suzhou Immunofoco Biotechnology Co., Ltd
Phase EARLY_PHASE1 Recruiting
NCT07493135 2026-03-30
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
Suzhou Immunofoco Biotechnology Co., Ltd
Phase EARLY_PHASE1 Recruiting
NCT04480645 2026-03-24
CivaDerm(TM) Surface Therapy Pilot Study
CivaTech Oncology
Phase EARLY_PHASE1 Completed
NCT07487597 2026-03-23
Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors
TCRCure Biopharma Ltd.
Phase EARLY_PHASE1 Recruiting
NCT06097962 2026-03-20
Safety and Efficacy of NK510 to Treat NSCLC
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT07468708 2026-03-12
The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer
FindCure Biosciences (ZhongShan) Co., Ltd.
Phase EARLY_PHASE1 Not yet recruiting
NCT07459283 2026-03-10
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
FindCure Biosciences (ZhongShan) Co., Ltd.
Phase EARLY_PHASE1 Not yet recruiting
NCT07274813 2026-03-03
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase EARLY_PHASE1 Recruiting
NCT06305962 2026-02-19
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
Radiopharm Theranostics, Ltd
Phase EARLY_PHASE1 Recruiting
NCT07412665 2026-02-17
A Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.
Beijing Geekgene Technology Co., LTD
Phase EARLY_PHASE1 Not yet recruiting
NCT07414316 2026-02-17
A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.
Beijing Geekgene Technology Co., LTD
Phase EARLY_PHASE1 Recruiting
NCT06824155 2026-02-11
RAD202
Radiopharm Theranostics, Ltd
Phase EARLY_PHASE1 Recruiting
NCT07327632 2026-02-04
This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors
Innovent Biologics Technology Limited (Shanghai R&D Center)
Phase EARLY_PHASE1 Recruiting
NCT07378436 2026-01-30
A Clinical Study of GK02 in Malignant Ascites
Beijing Geekgene Technology Co., LTD
Phase EARLY_PHASE1 Recruiting
NCT07108140 2026-01-22
Engineered T-cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors
TCRCure Biopharma Ltd.
Phase EARLY_PHASE1 Terminated
NCT06653023 2026-01-20
Wondercel-UWD3
Wondercel Biotech (ShenZhen)
Phase EARLY_PHASE1 Recruiting
NCT06662227 2026-01-20
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
Wondercel Biotech (ShenZhen)
Phase EARLY_PHASE1 Recruiting
NCT06663046 2026-01-20
Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma
Wondercel Biotech (ShenZhen)
Phase EARLY_PHASE1 Recruiting
NCT06653010 2026-01-16
Wondercel-UWD1
Wondercel Biotech (ShenZhen)
Phase EARLY_PHASE1 Recruiting
NCT07338604 2026-01-14
Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT07336823 2026-01-13
JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma
Shenzhen Genocury Biotech Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT07328087 2026-01-09
COLONYVAQ™-CRC
Biogenea Pharmaceuticals Ltd.
Phase EARLY_PHASE1 Recruiting
NCT07316361 2026-01-07
GYNORYLAQ™
Biogenea Pharmaceuticals Ltd.
Phase EARLY_PHASE1 Enrolling by invitation
NCT07312630 2025-12-31
Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT07131254 2025-12-30
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors
Grit Biotechnology
Phase EARLY_PHASE1 Recruiting
NCT06645808 2025-12-29
VARTUTRACE
Var2 Pharmaceuticals
Phase EARLY_PHASE1 Recruiting
NCT07205315 2025-12-26
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Grit Biotechnology
Phase EARLY_PHASE1 Recruiting
NCT04960072 2025-12-23
A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital)
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1 Recruiting
NCT06828328 2025-12-23
A Study of GC203 TIL in PDCA (RJ)
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1 Recruiting
NCT03433898 2025-12-19
This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer
Boehringer Ingelheim
Phase EARLY_PHASE1 Completed
NCT06488950 2025-12-16
A Study of TIL in Advanced Solid Tumors (DFGD)
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1 Recruiting
NCT07285434 2025-12-16
Microlyvaq™
Biogenea Pharmaceuticals Ltd.
Phase EARLY_PHASE1 Enrolling by invitation
NCT04943913 2025-12-11
Study of GC101 TIL in Brain Glioma (Soochow2)
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1 Recruiting
NCT04967833 2025-12-11
A Study of GC101 TIL in Advanced Solid Tumors (TR)
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1 Recruiting
NCT05098171 2025-12-11
A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital)
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1 Recruiting
NCT05098184 2025-12-11
A Study of GC101 TIL in Advanced Melanoma (10hospital)
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1 Recruiting
NCT05098197 2025-12-11
A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1 Recruiting
NCT05142475 2025-12-11
A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1 Recruiting
NCT05468307 2025-12-11
A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital)
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1 Completed
NCT05432375 2025-12-10
Study of Tinostamustine for Adjuvant Treatment of Glioblastoma
Mundipharma Research Limited
Phase EARLY_PHASE1 Completed
NCT07077616 2025-12-08
TAMAVAQTM
Biogenea Pharmaceuticals Ltd.
Phase EARLY_PHASE1 Recruiting
NCT07266311 2025-12-05
CAR-T for Claudin18.2 Positive Solid Tumors
Chengdu Ucello Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Not yet recruiting
NCT05021120 2025-12-04
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours
Akeso
Phase EARLY_PHASE1 Completed
NCT07246304 2025-11-24
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
TCRCure Biopharma Ltd.
Phase EARLY_PHASE1 Recruiting
NCT07243366 2025-11-21
Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis
Guangdong ProCapZoom Biosciences Co., Ltd.
Phase EARLY_PHASE1 Not yet recruiting
NCT04712721 2025-10-10
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
Novartis
Phase EARLY_PHASE1 Terminated